Moxifloxacin: Phase II started

The TB Alliance began the open-label, international Phase II NC-002 trial to evaluate the combination of PA-824, moxifloxacin and pyrazinamide for 8 weeks in about 230 patients. Patients will receive 100 or 200 mg PA-824 once daily in combination with 1,500 mg pyrazinamide once daily and 400 mg moxifloxacin once daily or Rifafour rifampicin/isoniazid/ethambutol/pyrimethamine as an active comparator. ...